首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 6期丙型肝炎 => 专家论坛 =>直接抗病毒药物联合PR方案(PEG-IF..
直接抗病毒药物联合PR方案(PEG-IFN联合利巴韦林)在丙型肝炎抗病毒治疗新时代的价值
Value of direct-acting antivirals combined with PR regimen (PEG-IFN combined with ribavirin) in the new era of antiviral therapy for hepatitis C
文章发布日期:2017年05月04日  来源:  作者:陈新月,柳雅立,任姗  点击次数:430次  下载次数:71次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:PEG-IFN联合利巴韦林(PR方案)在中国已有10多年的使用经验,随着直接抗病毒药物(DAA)的发展,丙型肝炎治疗方案出现多元化。DAA联合PR方案,在保留IFN有利慢性丙型肝炎(CHC)患者长期预后等优势的前提下使用DAA,可提高疗效、缩短疗程,进一步改善CHC的治疗现状。介绍PR、DAA联合PR及DAA全口服方案的优劣,旨在探讨更适合不同CHC患者的治疗方案,为临床实践提供参考。
【Abstract】:Pegylated interferon (PEG-IFN) combined with ribavirin (PR regimen) has been used in China for more than 10 years. With the development of direct-acting antiviral agents (DAAs), the therapeutic regimens for hepatitis C has become more and more diverse. In the regimen of DAAs combined with PR regimen, IFN helps to benefit the long-term prognosis of patients with chronic hepatitis C (CHC), and the addition of DAAs may improve therapeutic effect, shorten the course of treatment, and further improve the current status of treatment of CHC. This article introduces the advantages and disadvantages of PR regimen, DAAs combined with PR regimen, and oral regimen with DAAs, in order to investigate the therapeutic regimens suitable for different CHC patients and provide a reference for clinical practice.
【关键字】:肝炎, 丙型, 慢性; 抗病毒药; 治疗
【Key words】:hepatitis C, chronic; antiviral agents; therapy
【引证本文】:陈新月, 柳雅立, 任姗. 直接抗病毒药物联合PR方案(PEG-IFN联合利巴韦林)在丙型肝炎抗病毒治疗新时代的价值[J]. 临床肝胆病杂志, 2017, 33(6): 1063-1066.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号